Project 3. Cyclic nucleotides (cAMP and cGMP) are intracellular signaling molecules that are critical for the development and function ofthe brain. Deficits in cAMP/cGMP signaling have been repeatedly measured in patients with Alzheimer's disease and schizophrenia. Dysfunction ofthe hippocampus (HIPP) - a brain region that modulates affective, social, stress-related, and cognitive behaviors - has also been repeatedly implicated in these neuropsychiatric diseases. We believe that selectively restoring cyclic nucleotide signaling in the HIPP of patients, without affecting signaling in normal brain regions, would relieve neuropsychiatric disease-related symptoms without causing unwanted side effects. Phosphodiesterase 11A (PDE11A) is an enzyme that breaks down both cAMP and cGMP. We have recently discovered that PDE11A is almost exclusively localized to the HIPP. Thus, we hypothesize that cAMP/cGMP signaling in the HIPP can be selectively targeted by modulating PDE11A expression and/or function. Adult PDE11A knockout (KO) mice exhibit biochemical, anatomical, and behavioral deficits that are consistent with HIPP dysfunction and neuropsychiatric disease. This suggests that augmentation of PDE11A function may prove therapeutic. To increase function of a particular enzyme, we can increase either its availability (i.e., expression) or its catalytic activity. As such, we propose a series of aims designed to understand the molecular mechanisms controlling transcription and catalytic activity of PDE11 A.
In Specific Aim 1, we will determine if psychiatric disease is associated with changes in PDE11A transcription in brain and if cis-acting elements within the promoter of PDE11A are sufficient to restrict PDE11A mRNA expression to the HIPP in the healthy adult brain.
In Specific Aim 2, we will identify the signaling cascades and trans-acting proteins that control PDE11A promoter activity.
In Specific Aim 3, we will develop small molecule PDE11A activators and test them in PDE11A wild-type and KO mice (KOs = negative controls) using a neuropsychiatric battery that assesses efficacy and side effect liability. PDE11A may be capable of selectively restoring cAMP and cGMP signaling in a specific brain region impacted by disease, without affecting signaling elsewhere.

Public Health Relevance

Deficits in cAMP and cGMP signaling have been repeatedly measured in patients with Alzheimer's disease and schizophrenia. This proposal seeks to better understand how we can control the transcription and catalytic activity of Phosphodiesterase 11 A, an enzyme that breaks down cAMP and cGMP. In so doing, we hope to identify a therapeutic path forward to rescue the cAMP and cGMP deficits associated with neuropsychiatric diseases

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Exploratory Grants (P20)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-TWD-A (C1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of South Carolina at Columbia
United States
Zip Code
Lunev, Sergey; Semmelink, Marije F W; Xian, Jia Ling et al. (2017) Crystal structure of truncated human coatomer protein complex subunit ?1 (Cop?1). Acta Crystallogr F Struct Biol Commun 73:1-8
McDermott, Martina S J; Chumanevich, Alexander A; Lim, Chang-Uk et al. (2017) Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget 8:12558-12575
Chen, Mengqian; Liang, Jiaxin; Ji, Hao et al. (2017) CDK8/19 Mediator kinases potentiate induction of transcription by NF?B. Proc Natl Acad Sci U S A 114:10208-10213
Vassoler, Fair M; Oliver, David J; Wyse, Cristina et al. (2017) Transgenerational attenuation of opioid self-administration as a consequence of adolescent morphine exposure. Neuropharmacology 113:271-280
Varadaraj, Archana; Jenkins, Laura M; Singh, Priyanka et al. (2017) TGF-? triggers rapid fibrillogenesis via a novel T?RII-dependent fibronectin-trafficking mechanism. Mol Biol Cell 28:1195-1207
Oliver, David; Ji, Hao; Liu, Piaomu et al. (2017) Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen. Sci Rep 7:43023
Choi, Ran Hee; McConahay, Abigail; Jeong, Ha-Won et al. (2017) Tribbles 3 regulates protein turnover in mouse skeletal muscle. Biochem Biophys Res Commun 493:1236-1242
Markoutsa, Eleni; Xu, Peisheng (2017) Redox Potential-Sensitive N-Acetyl Cysteine-Prodrug Nanoparticles Inhibit the Activation of Microglia and Improve Neuronal Survival. Mol Pharm 14:1591-1600
Yu, Jin; Zhu, Hong; Perry, Stephen et al. (2017) Daily supplementation with GrandFusion® improves memory and learning in aged rats. Aging (Albany NY) 9:1041-1054
He, Huacheng; Markoutsa, Eleni; Zhan, Yihong et al. (2017) Mussel-inspired PLGA/polydopamine core-shell nanoparticle for light induced cancer thermochemotherapy. Acta Biomater 59:181-191

Showing the most recent 10 out of 36 publications